银屑病共病的研究进展

doi:10.35541/cjd.20190093

中华皮肤科杂志 ›› 2020, Vol. 53 ›› Issue (2): 147-151.doi: 10.35541/cjd.20190093

银屑病共病的研究进展

陈文娟¹ 彭琛¹ 丁杨峰¹ 史玉玲²

¹同济大学医学院银屑病研究所上海市皮肤病医院皮肤内科，上海 200443；²同济大学医学院银屑病研究所同济大学附属第十人民医院皮肤性病科，上海 200072

收稿日期:2018-12-07 修回日期:2019-06-16 发布日期:2020-02-01
通讯作者: 史玉玲 E-mail:shiyuling1973@tongji.edu.cn
基金资助:
国家自然科学基金（81872522、81673050）；上海市科委科研计划项目（18140901800）；上海市教委科研创新计划项目（2019-01-07-00-07-E00046）；上海市卫生系统优秀人才培养计划项目（2018BR30）；上海申康医院发展中心临床科技创新项目（SHDC12018X06）

Psoriasis comorbidities

Chen Wenjuan¹, Peng Chen¹, Ding Yangfeng¹, Shi Yuling²

¹Institute of Psoriasis, Tongji University School of Medicine, Department of Dermatology, Shanghai Skin Disease Hospital, Shanghai 200443, China;²Institute of Psoriasis, Tongji University School of medicine, Department of Dermatology and Venereology, Tenth People′s Hospital of Tongji University, Shanghai 200072, China

Received:2018-12-07 Revised:2019-06-16 Published:2020-02-01
Contact: Shi Yuling E-mail:shiyuling1973@tongji.edu.cn
Supported by:
National Natural Science Foundation of China （81872522, 81673050）; Shanghai Science and Technology Commission "Science and Technology Innovation Action Plan" （18140901800）; Scientific Research Innovation Project of Shanghai Municipal Education Commission （2019-01-07-00-07-E00046）; Excellent Talents Training Project in Shanghai Health System （2018BR30）; Clinical Science and Technology Innovation Project of Shanghai Shen-kang Hospital Development Center （SHDC12018X06）

摘要/Abstract

摘要： 【摘要】银屑病是一种免疫介导的慢性炎症性皮肤病，其发病与基因、免疫、环境等因素密切相关。传统的与银屑病相关的共病主要包括心血管疾病、肥胖和炎症性肠病等，越来越多的研究发现其他一些疾病与银屑病之间的密切关联，包括代谢综合征、慢性肾脏疾病、肿瘤、感染等。本文总结现有研究报道的银屑病相关共病，分析这些疾病与银屑病可能的共同发病机制。

关键词: 银屑病, 共病现象, 心血管疾病, 糖尿病, 肥胖症, 代谢疾病, 自身免疫疾病

Abstract: 【Abstract】 Psoriasis is an immune-mediated chronic inflammatory disease, whose occurrence is closely associated with genes, immunity, environment and other factors. Classic comorbidities associated with psoriasis mainly include cardiovascular diseases, obesity and inflammatory bowel diseases. Emerging data have shown some other diseases closely associated with psoriasis, including metabolic syndrome, chronic renal diseases, tumors, infections, and so on. This review summarizes psoriasis-associated comorbidities that have been reported in studies, and analyzes the possible co-pathogenesis of these diseases and psoriasis.

Key words: Psoriasis, Comorbidity, Cardiovascular diseases, Diabetes mellitus, Obesity, Metabolic diseases, Autoimmune diseases

陈文娟彭琛丁杨峰史玉玲. 银屑病共病的研究进展[J]. 中华皮肤科杂志, 2020,53(2):147-151. doi:10.35541/cjd.20190093

Chen Wenjuan, Peng Chen, Ding Yangfeng, Shi Yuling. Psoriasis comorbidities[J]. Chinese Journal of Dermatology, 2020, 53(2): 147-151.doi:10.35541/cjd.20190093

参考文献 57

［1］	Reed WB, Becker SW, Rohde R, et al. Psoriasis and arthritis. Clinicopathologic study［J］. Arch Dermatol, 1961,83:541⁃548.
［2］	Alexander E, Pinto J, Pal GS, et al. Disease concomitance in psoriasis: a clinical study of 61 cases［J］. Indian J Dermatol Venereol Leprol, 2001,67（2）:66⁃68.
［3］	Samarasekera EJ, Neilson JM, Warren RB, et al. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta⁃analysis［J］. J Invest Dermatol, 2013,133（10）:2340⁃2346. doi: 10.1038/jid.2013.149.
［4］	Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta⁃analysis of observational studies［J］. J Am Heart Assoc, 2013,2（2）:e000062. doi: 10.1161/JAHA.113.000062.
［5］	Shen J, Wong KT, Cheng IT, et al. Increased prevalence of coronary plaque in patients with psoriatic arthritis without prior diagnosis of coronary artery disease［J］. Ann Rheum Dis, 2017,76（7）:1237⁃1244. doi: 10.1136/annrheumdis⁃2016⁃210390.
［6］	Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis［J］. JAMA, 2006,296（14）:1735⁃1741. doi: 10.1001/jama.296.14.1735.
［7］	Picard D, Bénichou J, Sin C, et al. Increased prevalence of psoriasis in patients with coronary artery disease: results from a case⁃control study［J］. Br J Dermatol, 2014,171（3）:580⁃587. doi: 10.1111/bjd.13155.
［8］	Xiao J, Chen LH, Tu YT, et al. Prevalence of myocardial infarction in patients with psoriasis in central China［J］. J Eur Acad Dermatol Venereol, 2009,23（11）:1311⁃1315. doi: 10.1111/ j.1468⁃3083.2009.03318.x.
［9］	Parisi R, Rutter MK, Lunt M, et al. Psoriasis and the risk of major cardiovascular events: cohort study using the clinical practice research datalink［J］. J Invest Dermatol, 2015,135（9）:2189⁃2197. doi: 10.1038/jid.2015.87.
［10］	Dowlatshahi EA, Kavousi M, Nijsten T, et al. Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study［J］. J Invest Dermatol, 2013,133（10）:2347⁃2354. doi: 10.1038/jid.2013.131.
［11］	Lockshin B, Balagula Y, Merola JF. Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis［J］. J Am Acad Dermatol, 2018,79（2）:345⁃352. doi: 10.1016/j.jaad.2018.02.040.
［12］	Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta⁃analysis of observational studies［J］. J Hypertens, 2013,31（3）:433⁃443. doi: 10.1097/HJH.0b013e32 835bcce1.
［13］	Kim HN, Han K, Song SW, et al. Hypertension and risk of psoriasis incidence: an 11⁃year nationwide population⁃based cohort study［J/OL］. PLoS One, 2018,13（8）:e0202854. doi: 10.1371/ journal.pone.0202854.
［14］	Wu S, Han J, Li WQ, et al. Hypertension, antihypertensive medication use, and risk of psoriasis［J］. JAMA Dermatol, 2014,150（9）:957⁃963. doi: 10.1001/jamadermatol.2013.9957.
［15］	Daudén E, Castañeda S, Suárez C, et al. Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis［J］. J Eur Acad Dermatol Venereol, 2013,27（11）:1387⁃1404. doi: 10.1111/jdv.12024.
［16］	Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co⁃morbid conditions［J］. J Invest Dermatol, 2010,130（7）:1785⁃1796. doi: 10.1038/jid.2010.103.
［17］	Lee MS, Lin RY, Lai MS. Increased risk of diabetes mellitus in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population⁃based cohort study［J］. J Am Acad Dermatol, 2014,70（4）:691⁃698. doi: 10.1016/j.jaad. 2013.11.023.
［18］	Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology［J］. J Am Acad Dermatol, 2017,76（3）:377⁃390. doi: 10.1016/j.jaad.2016.07.064.
［19］	Lønnberg AS, Skov L, Skytthe A, et al. Association of psoriasis with the risk for type 2 diabetes mellitus and obesity［J］. JAMA Dermatol, 2016,152（7）:761⁃767. doi: 10.1001/jamadermatol. 2015.6262.
［20］	Armstrong AW, Guérin A, Sundaram M, et al. Psoriasis and risk of diabetes⁃associated microvascular and macrovascular complications［J］. J Am Acad Dermatol, 2015,72（6）:968⁃977.e2. doi: 10.1016/j.jaad.2015.02.1095.
［21］	Gyldenløve M, Storgaard H, Holst JJ, et al. Patients with psoriasis are insulin resistant［J］. J Am Acad Dermatol, 2015,72（4）:599⁃605. doi: 10.1016/j.jaad.2015.01.004.
［22］	Oliveira Mde F, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities［J］. An Bras Dermatol, 2015,90（1）:9⁃20. doi: 10.1590/abd1806⁃4841.20153038.
［23］	Jensen P, Skov L. Psoriasis and obesity［J］. Dermatology, 2016,232（6）:633⁃639. doi: 10.1159/000455840.
［24］	Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis［J］. J Am Acad Dermatol, 2006,55（5）:829⁃835. doi: 10.1016/j.jaad.2006. 08.040.
［25］	Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome. A cross⁃sectional study［J］. Dermatology, 2008,216（2）:152⁃155. doi: 10.1159/000111 512.
［26］	Upala S, Sanguankeo A. Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta⁃analysis［J］. Int J Obes （Lond）, 2015,39（8）:1197⁃1202. doi: 10.1038/ijo.2015.64.
［27］	Cao H. Adipocytokines in obesity and metabolic disease［J］. J Endocrinol, 2014,220（2）:T47⁃59. doi: 10.1530/JOE⁃13⁃0339.
［28］	Gómez R, Conde J, Scotece M, et al. What′s new in our understanding of the role of adipokines in rheumatic diseases?［J］. Nat Rev Rheumatol, 2011,7（9）:528⁃536. doi: 10.1038/nrrheum.2011.107.
［29］	Salahuddin T, Natarajan B, Playford MP, et al. Cholesterol efflux capacity in humans with psoriasis is inversely related to non⁃calcified burden of coronary atherosclerosis［J］. Eur Heart J, 2015,36（39）:2662⁃2665. doi: 10.1093/eurheartj/ehv339.
［30］	Kotronen A, Yki⁃Järvinen H. Fatty liver: a novel component of the metabolic syndrome［J］. Arterioscler Thromb Vasc Biol, 2008,28（1）:27⁃38. doi: 10.1161/ATVBAHA.107.147538.
［31］	Radtke MA, Mrowietz U, Feuerhahn J, et al. Early detection of comorbidity in psoriasis: recommendations of the National Conference on Healthcare in Psoriasis［J］. J Dtsch Dermatol Ges, 2015,13（7）:674⁃690. doi: 10.1111/ddg.12643.
［32］	Rodríguez⁃Zúñiga M, García⁃Perdomo HA. Systematic review and meta⁃analysis of the association between psoriasis and metabolic syndrome［J］. J Am Acad Dermatol, 2017,77（4）:657⁃666.e8. doi: 10.1016/j.jaad.2017.04.1133.
［33］	Gui XY, Yu XL, Jin HZ, et al. Prevalence of metabolic syndrome in Chinese psoriasis patients: a hospital⁃based cross⁃sectional study［J］. J Diabetes Investig, 2018,9（1）:39⁃43. doi: 10.1111/jdi.12663.
［34］	Chi C, Wang J, Chen Y, et al. Risk of incident chronic kidney disease and end⁃stage renal disease in patients with psoriasis: a nationwide population⁃based cohort study［J］. Value Health, 2015,18（7）:A415. doi: 10.1016/j.jval.2015.09.1004.
［35］	Yang YW, Keller JJ, Lin HC. Medical comorbidity associated with psoriasis in adults: a population⁃based study［J］. Br J Dermatol, 2011,165（5）:1037⁃1043. doi: 10.1111/j.1365⁃2133. 2011.10494.x.
［36］	Wan J, Wang S, Haynes K, et al. Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study［J］. BMJ, 2013,347:f5961. doi: 10.1136/bmj.f5961.
［37］	Merola JF, Wu S, Han J, et al. Psoriasis, psoriatic arthritis and risk of gout in US men and women［J］. Ann Rheum Dis, 2015,74（8）:1495⁃1500. doi: 10.1136/annrheumdis⁃2014⁃205212.
［38］	Gisondi P, Galvan A, Idolazzi L, et al. Management of moderate to severe psoriasis in patients with metabolic comorbidities［J］. Front Med （Lausanne）, 2015,2:1. doi: 10.3389/fmed.2015.00001.
［39］	Gelfand JM, Shin DB, Neimann AL, et al. The risk of lymphoma in patients with psoriasis［J］. J Invest Dermatol, 2006,126（10）:2194⁃2201. doi: 10.1038/sj.jid.5700410.
［40］	Geller S, Xu H, Lebwohl M, et al. Malignancy risk and recurrence with psoriasis and its treatments: a concise update［J］. Am J Clin Dermatol, 2018,19（3）:363⁃375. doi: 10.1007/s40257⁃017⁃0337⁃2.
［41］	Gu Y, Nordstrom BL. The risk of malignancy among biologic⁃naïve pediatric psoriasis patients: a retrospective cohort study in a US claims database［J］. J Am Acad Dermatol, 2017,77（2）:293⁃301.e1. doi: 10.1016/j.jaad.2017.03.044.
［42］	Wu JJ, Nguyen TU, Poon KY, et al. The association of psoriasis with autoimmune diseases［J］. J Am Acad Dermatol, 2012,67（5）:924⁃930. doi: 10.1016/j.jaad.2012.04.039.
［43］	Alidrisi HA, Al Hamdi K, Mansour AA. Is there any association between psoriasis and hashimoto′s thyroiditis?［J］. Cureus, 2019,11（3）:e4269. doi: 10.7759/cureus.4269.
［44］	Chi CC, Tung TH, Wang J, et al. Risk of uveitis among people with psoriasis: a nationwide cohort study［J］. JAMA Ophthalmol, 2017,135（5）:415⁃422. doi: 10.1001/jamaophthalmol.2017.0569.
［45］	Fu Y, Lee CH, Chi CC. Association of psoriasis with inflammatory bowel disease: a systematic review and meta⁃analysis［J］. JAMA Dermatol, 2018,154（12）:1417⁃1423. doi: 10.1001/jamadermatol. 2018.3631.
［46］	Pietrzak D, Pietrzak A, Krasowska D, et al. Correction to: digestive system in psoriasis: an update［J］. Arch Dermatol Res, 2017,309（9）:695⁃696. doi: 10.1007/s00403⁃017⁃1788⁃2.
［47］	Galili E, Barzilai A, Shreberk⁃Hassidim R, et al. Neuropsychiatric comorbidity among adolescents with psoriasis［J］. Br J Dermatol, 2018,178（4）:910⁃916. doi: 10.1111/bjd.16031.
［48］	Aleem D, Tohid H. Pro⁃inflammatory cytokines, biomarkers, genetics and the immune system: a mechanistic approach of depression and psoriasis［J］. Rev Colomb Psiquiatr, 2018,47（3）:177⁃186. doi: 10.1016/j.rcp.2017.03.002.
［49］	Strober B, Gooderham M, de Jong E, et al. Depressive symptoms, depression, and the effect of biologic therapy among patients in psoriasis longitudinal assessment and registry （PSOLAR）［J］. J Am Acad Dermatol, 2018,78（1）:70⁃80. doi: 10.1016/j.jaad. 2017.08.051.
［50］	Christophers E. Periodontitis and risk of psoriasis: another comorbidity［J］. J Eur Acad Dermatol Venereol, 2017,31（5）:757⁃758. doi: 10.1111/jdv.14249.
［51］	Papadavid E, Dalamaga M, Vlami K, et al. Psoriasis is associated with risk of obstructive sleep apnea independently from metabolic parameters and other comorbidities: a large hospital⁃based case⁃control study［J］. Sleep Breath, 2017,21（4）:949⁃958. doi: 10.1007/s11325⁃017⁃1507⁃4.
［52］	Chiang YY, Lin HW. Association between psoriasis and chronic obstructive pulmonary disease: a population⁃based study in Taiwan［J］. J Eur Acad Dermatol Venereol, 2012,26（1）:59⁃65. doi: 10.1111/j.1468⁃3083.2011.04009.x.
［53］	Pedreira PG, Pinheiro MM, Szejnfeld VL. Bone mineral density and body composition in postmenopausal women with psoriasis and psoriatic arthritis［J］. Arthritis Res Ther, 2011,13（1）:R16. doi: 10.1186/ar3240.
［54］	Molina⁃Leyva A, Jiménez⁃Moleón JJ, Naranjo⁃Sintes R, et al. Sexual dysfunction in psoriasis: a systematic review［J］. J Eur Acad Dermatol Venereol, 2015,29（4）:649⁃655. doi: 10.1111/jdv. 12845.
［55］	Lebwohl M. Does treatment of psoriasis reduce cardiovascular comorbidities?［J］. J Invest Dermatol, 2017,137（8）:1612⁃1613. doi: 10.1016/j.jid.2017.06.001.
［56］	Shiga H, Fukuda S, Iijima K. Interleukin⁃17A inhibitor⁃induced Crohn′s disease/Behçet′s disease⁃like Lesions［J］. Inflamm Bowel Dis, 2017,23（6）:E38⁃38E39. doi: 10.1097/MIB.0000000 000001142.
［57］	Xu X, Lin L, Chen P, et al. Treatment with liraglutide, a glucagon⁃like peptide⁃1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study［J］. Diabetes Res Clin Pract, 2019,150:167⁃173. doi: 10. 1016/j.diabres.2019.03.002.

[1]	付丹丹李佳林付修宇张芯育胡华宋向凤田中伟. S100A10蛋白在银屑病皮损的表达及对小鼠银屑病样皮炎模型的影响[J]. 中华皮肤科杂志, 2023, 56(9): 839-844.
[2]	荆可王媛李锁冯素英. 表现为环状红斑水疱的自身免疫性表皮下水疱病25例回顾性分析[J]. 中华皮肤科杂志, 2023, 56(9): 832-838.
[3]	刘小扬赵琰蔡林张建中. 银屑病患者白细胞介素17拮抗剂治疗后出现特应性皮炎样皮疹4例分析与文献回顾[J]. 中华皮肤科杂志, 2023, 56(9): 845-848.
[4]	陈小敏张景展丁媛康晓静. 二甲双胍治疗银屑病的研究进展[J]. 中华皮肤科杂志, 2023, 56(8): 799-802.
[5]	蒋晓妍高敏张晓艳刘宁远. 白细胞介素17和白细胞介素23拮抗剂治疗脓疱型银屑病研究进展[J]. 中华皮肤科杂志, 2023, 56(7): 689-692.
[6]	闪莹常晓彤左亚刚. 自身免疫性疱病的表位扩展现象[J]. 中华皮肤科杂志, 2023, 56(7): 702-705.
[7]	唐志铭荆梦晴陆鹭单霄张翠侠张晓宇孟飒. 犀地凉血方通过LncRNA NEAT1/miR-485-5p/ STAT3调控网络对HaCaT细胞增殖、凋亡影响的研究[J]. 中华皮肤科杂志, 2023, 56(7): 642-650.
[8]	中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2023版）[J]. 中华皮肤科杂志, 2023, 56(7): 573-625.
[9]	苏畅隋秀丽刘瑞玲曹毅群姜虹严彩蓉王惠平亓玉青. [开放获取] 奥马珠单抗治疗慢性自发性荨麻疹伴有其他过敏性疾病患者74例临床分析[J]. 中华皮肤科杂志, 2023, 56(6): 512-517.
[10]	中国医师协会皮肤科医师分会中华医学会皮肤性病学分会空军军医大学西京医院中国银屑病患者饮食指南制订工作组. 中国银屑病患者饮食管理指南（2023）[J]. 中华皮肤科杂志, 2023, 56(5): 389-401.
[11]	金利平朱武鲁艳刘盼盼谭敏佳王英杨晶徐黎聪胡琨匡叶红. 饮食干预治疗银屑病的相关进展[J]. 中华皮肤科杂志, 2023, 56(4): 357-360.
[12]	连盼盼刘军苏忠兰王宏伟. 过氧化物酶体增殖物激活受体γ对皮肤生理功能和病理过程的影响[J]. 中华皮肤科杂志, 2023, 56(4): 365-368.
[13]	何谐栗玉珍. 靶向JAK-STAT信号通路治疗银屑病的研究进展[J]. 中华皮肤科杂志, 2023, 56(3): 273-278.
[14]	阮诗钒张鹏林婷婷罗仁炜鲍思怡薛晨瑶童泽群张亮亮龚婷纪超. 寻常型银屑病与血脂异常的相关性研究[J]. 中华皮肤科杂志, 2023, 0(3): 20220322-e20220322.
[15]	中华医学会皮肤性病学分会银屑病专业委员会. 银屑病生物制剂达标治疗专家共识[J]. 中华皮肤科杂志, 2023, 56(3): 191-203.

银屑病共病的研究进展

Psoriasis comorbidities

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 57

相关文章 15

Metrics

本文评价

推荐阅读 10